Saturday, March 29 — Morning Events

4501. Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data
Hyatt Regency McCormick Place, Regency Ballroom AB (Second Floor)
6:15 – 7:45 a.m.
Provided by PVI, PeerView Institute for Medical Education in partnership with The Mended Hearts, Inc. This activity is supported by an educational grant from Bristol Myers Squibb.

Hypertrophic cardiomyopathy (HCM) affects as many as 1 in 200 individuals, with obstructive HCM (oHCM) having been managed historically with therapies directed at symptoms, as well as by invasive procedures used for more severe forms of this progressive disease. Cardiac myosin inhibitors (CMIs), which target the underlying pathophysiology of HCM, have emerged in recent years, improving symptomatic and functional outcomes, reshaping the treatment algorithm, and reducing reliance on surgical interventions. Join us for this expert-led MasterClass & Case Forum to level up your HCM expertise bolstered by accumulating long-term data and real-world experience with innovative approaches to HCM diagnosis and treatment. Learn more and register.

Speakers

Milind Desai, MD, MBA, FACC, FAHA, FESC
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Vice Chair of Education
Co-director, Cardiovascular Imaging Laboratories (CT and CMR)
Director, HCM Center
Medical Director, Aorta Center
Heart Vascular Thoracic Institute
Director of Clinical Operations of Cardiovascular Medicine
Cleveland Clinic
Cleveland, Ohio

Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

4502. Beyond Left Ventricular Hypertrophy in HCM: A Patient Journey to Achieve Equitable Care
Marriott Marquis Chicago
Grand Horizon C – Level 4
6 – 7:30 a.m.

Significant disparities in the healthcare system limit access to specialized care, advanced diagnostics, and novel treatments for hypertrophic cardiomyopathy (HCM), particularly affecting patients in rural, underserved, and minority communities. Barriers such as inadequate referral pathways, insurance coverage issues, and socioeconomic factors delay diagnosis and hinder access to advanced and disease-modifying therapies. Additionally, the underrepresentation of minority populations in HCM clinical trials compromises the applicability of research findings to diverse patient groups, further exacerbating inequities in care.

Join our esteemed panel of experts to learn about HCM in underserved and minority populations focusing on key diagnostic challenges, access to medical therapy and emerging treatments, and how to address systemic inequities through shared decision making to improve outcomes and quality of life for all patients with HCM. To learn more visit: www.medscape.org/sympo/hcm-equity

Speakers

Carolyn Y. Ho, MD
Professor of Medicine, Harvard Medical School
Medical Director, Cardiovascular Genetics Center
Brigham and Women's Hospital
Boston, Massachusetts

Nosheen Reza, MD, MS, FACC, FHFSA
Assistant Professor of Medicine
Penn Center for Inherited Cardiovascular Disease
Section of Advanced Heart Failure, Transplantation, and Mechanical Support
University of Pennsylvania
Philadelphia, Pennsylvania

Sharon Cresci, MD
Professor of Medicine and Genetics
Associate director, WUMS/BJH Hypertrophic Cardiomyopathy Center
Director, IMPACT (Initiative for Mentoring, Promoting Networking and Advocacy for Cardiology Trainees)
Washington University
Cardiovascular Division
St Louis, Missouri

Sponsored by an independent educational grant from Cytokinetics

Saturday, March 29 — Evening Events

4504. RNAi Science & Therapeutic Innovation: Past, Present and Future
Renaissance Chicago Downtown
Grand Ballroom
1 West Upper Wacker Drive
Chicago, Illinois, USA, 60601
7:00-9:00pm
Sponsored by Alnylam Pharmaceuticals

Following this interactive symposium, attendees will:

• Understand the historical context and key developments in RNAi science leading to an innovative class of medicines.
• Understand current applications of RNAi therapeutics in diseases with high unmet needs, including ATTR amyloidosis.
• Understand potential future directions for investigational RNAi therapeutics, including hypertension.

4505. Meeting the Challenge: Transforming Patient Care in sHTG and FCS With Novel RNA-Based Therapies
Hyatt Regency McCormick Place
Prairie Room
2233 S. Martin Luther King Drive
Chicago, Illinois 60616
6:30 – 8:30 p.m.
Sponsored by a grant from Ionis Pharmaceuticals, Inc.

Join leading experts at this ACC satellite symposium to explore the latest advancements in RNA-based therapies for severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS). Gain insights into emerging clinical data, patient selection, and the evolving treatment landscape to optimize care for these high-risk patients.

Speakers

Christie M. Ballantyne, MD
United States of America
JS Abercrombie Chair, Atherosclerosis and Lipoprotein Research
Professor of Medicine and Molecular and Human Genetics
Baylor College of Medicine
Chief, Cardiology and Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Texas Heart Institute and Baylor College of Medicine
Houston, Texas

Michael D. Shapiro, DO, MCR, FACC, FAHA
Fred M. Parrish Professor of Cardiology and Molecular Medicine
Director, Center for Prevention of Cardiovascular Disease
Section on Cardiovascular Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

4506. Breaking News: Advances in Heart Failure Management
Marriott Marquis Chicago
Grand Horizon BC
7 – 8:15 p.m.
Sponsored by an independent educational grant from Bayer

Despite the implementation of guideline-directed medical therapies (GDMT) for heart failure, a persistent and high level of "residual risk" remains, comparable with or even worse than other major cardiovascular diseases. Additionally, many vulnerable patients who are unable to tolerate optimal doses of GDMT, whether due to adverse events or comorbidities, are at even greater risk. In this Medscape Report symposium, our expert faculty will bring you the latest data on emerging therapies for heart failure in a high-energy, newsroom setting. To learn more visit: www.medscape.org/symposium/breaking-news-hf

Speakers

Alok S. Patel, MD
Pediatrician
Stanford Children's Health
Palo Alto, California

Javed Butler, MD, MPH, MBA
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi
Maxwell A. and Gayle H. Clampitt Endowed Chair
President and Chief Research Executive
Baylor Scott and White Research Institute
Senior Vice President
Baylor Scott and White Health
Dallas, Texas

Andrew J. Sauer, MD
Associate Professor
Saint Luke's Mid America Heart Institute
Kansas City, Missouri

Harriette G.C. Van Spall, MD, MPH
Associate Professor of Medicine, Division of Cardiology
Michael G. DeGroote School of Medicine
McMaster University
Ontario, Canada

Sunday, March 30 – Morning Events

4507. Teaming Up in the Race to Conquer Hypertension Management
Marriott Marquis Chicago
Grand Horizon C – Level 4
6 – 7:30 a.m.
Sponsored by an independent education grant from Idorsia

Hypertension (HTN) is the most common risk factor for cardiovascular (CV) morbidity and mortality worldwide, affecting nearly 1.28 billion adults. In the United States, almost half of the adult population has HTN, and the condition is uncontrolled in more than three-quarters of these individuals. Furthermore, more than 33 million adults in the United States have uncontrolled HTN despite being treated with antihypertensive medications. The persistent high prevalence of uncontrolled HTN not only puts patients at increased risk for CV events, but also contributes to higher healthcare costs due to the need for more intensive medical interventions and hospitalizations.

In this engaging virtual race our panel of experts will present real world patient cases and request your input on clinical decisions on the diagnosis and management of uncontrolled/resistant HTN, current treatment strategies, and where new therapies fit into clinical practice. Join us for a fun learning experience and lead your team to victory! To Learn more visit: www.medscape.org/sympo/resistant-hypertension

Speakers

Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Gerald S. Berenson Endowed Chair in Preventative Cardiology
Professor of Medicine,
Tulane University School of Medicine
New Orleans, Louisiana

Alexander Blood, MD
Associate Director, Accelerator for Clinical Transformation
Brigham and Women's Hospital
Instructor, Department of Medicine
Harvard Medical School
Medical Director, Cardiovascular Critical Care Unit
Newton Wellesley Hospital
Boston, Massachusetts

Markus P. Schlaich, MD
Winthrop Professor
Dobney Chair in Clinical Research
School of Medicine
Royal Perth Hospital Unit

4508. Do It Better: Raising the Bar in Heart Failure Care With Practical Strategies For Treatment With SGLT2 Inhibitors
Hyatt Regency McCormick Place
Prairie Room
2233 S Martin Luther King Dr.
Chicago, Illinois 60616
5:45 - 7:45 a.m.
Sponsored by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

Join leading experts at this live satellite symposium at ACC.25, focusing on addressing clinical gaps in heart failure management, evaluating the benefits of SGLT2 inhibitors, and providing practical strategies for their integration into guideline-directed therapy to improve cardiovascular outcomes across the spectrum of left ventricular ejection fraction.

Speakers

Javed Butler, MD, MPH, MBA
President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Ty J. Gluckman, MD, MHA
Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

4509. Title, time and location to be announced
Sponsored by Viatris

Sunday, March 30 – Evening Events

4510. Referral of Patients With Severe Aortic Stenosis: Are the Pathways Changing?
Hyatt Regency McCormick Place, Prairie Room, 2nd Floor
6:30 p.m.
Provided by Haymarket Medical Education Independent medical education funding from Edwards Lifesciences, LLC.

This symposium features a roundtable discussion among front-line researchers regarding the latest clinical data in the management of severe aortic stenosis. The expert faculty will discuss how these findings may impact patient pathways–including the benefits of prompt referral and early intervention to achieve optimal outcomes in this challenging patient population. Reserve your spot.

Speakers

Sreekanth Vemulapalli, MD
Associate Professor of Medicine
Medical Director, Duke Echo Lab and Cardiac Diagnostic Unit
Duke Clinical Research Institute
Duke-Margolis Institute for Health Policy
Durham, NC

Sammy Elmariah, MD, MPH
Chief, Interventional Cardiology
Director, UCSF Cardiac
Catheterization Laboratory
Associate Professor of Medicine
University of California San Francisco
San Francisco, CA

Philippe Généreux, MD
Medical Director, Structural Heart Center
Gagnon Cardiovascular Institute
Morristown Medical Center
Morristown, NJ

Linda D. Gillam, MD, MPH
Dorothy and Lloyd Huck Chair of Cardiovascular Medicine
Medical Director of the Cardiovascular Service Line, Atlantic Health System
Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University
Morristown, NJ

Brian R. Lindman, MD, MSCI
Medical Director, Structural Heart and Valve Center
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

Mark J. Russo, MD, MS
Professor of Surgery, Chief of Cardiac Surgery
Director of Structural Heart Disease
Rutgers-Robert Wood Johnson Medical School
New Brunswick, NJ

David A. Wood, MD, FRCPC, FACC, FSCAI, FESC
Professor, Head of Cardiology
Vancouver General Hospital and the University of British Columbia (UBC) Hospital
Director, UBC Centre for Cardiovascular Innovation and VGH Cardiac Catheterization Laboratory
Vancouver, BC, Canada

4511. Decisive Coronary Care: The Role of CCTA and AI in CAD Management
Hyatt Regency McCormick Place, Regency Ballroom AB
6:30 p.m.
Sponsored by HeartFlow
Join us for a discussion on how Coronary CTA advancements and AI-driven insights are transforming personalized risk assessment and treatment. We'll explore the latest clinical evidence and real-world applications of Heartflow in assessing anatomy, physiology, and plaque. Learn how plaque quantification and FFRCT analysis are reshaping clinical practice.

Speakers

Leslee J. Shaw, PhD, MASNC, FACC, FAHA, MSCCT
Professor of Medicine (Cardiology), Population Health Science, and Obstetrics, Gynecology, and Reproductive Science
Director, Blavatnik Family Women's Health Research Institute

Allen J. Taylor, MD, FACC, FAHA
Chairman of Cardiology
MedStar Heart and Vascular Institute

Matthew Budoff, MD, FACC, FAHA
Professor of Medicine, UCLA
Endowed Chair of Preventive Cardiology
Lundquist Institute at Harbor-UCLA, Torrance, CA

4512. NewAmsterdam Pharma "Expect More" Drone Show Event
Michigan Avenue, across from Grant Park
8:30 p.m.
Sponsored by NewAmsterdam Pharma

NewAmsterdam Pharma presents a one-of-a-kind drone show about the rising threat of ASCVD.

Please be advised that the "viewing area" is along Michigan Avenue, across from Grant Park. The drones will take flight from a central location in Grant Park and be "viewable" in the sky from a 1-mile radius in all directions.